Repatha (evolocumab)

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from

Repatha® Outcomes study -
results now available!

EUHQ-P-145-0317-046541 – Date of preparation: March 2017
Repatha (evolocumab)

Therapeutic indications1

Repatha® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Repatha® is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.

The effect of Repatha® on cardiovascular morbidity and mortality has not yet been determined.

This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc

CV = Cardiovascular; LDL-C = Low-density lipoprotein cholesterol.

  1. Repatha® (evolocumab) Summary of Product Characteristics.